After 90 days, patients who received an investigational proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor known as PCSK9i had significant and durable reductions in low-density lipoprotein (LDL) cholesterol, according to an interim analysis of a phase 1 study.

Leonhard Lang recalled its defibrillation electrode due to a connector compatibility issue with model 10 of the Welch Allyn automatic external defibrillator (AED).

Five months after the FDA rejected the approval of sodium zirconium cyclosilicate (ZS-9), the agency accepted a resubmission of the new drug application, according to an AstraZeneca news release.

To better use technology to treat congestive heart failure, New York’s Mount Sinai Hospital has plans to use CloudMedx Clinical AI Platform, an artificial intelligence services software, reports Fortune.

Physicians typically prescribe statins to lower cholesterol and help reduce the risk of MIs and strokes. The medications have proven to work in numerous clinical trials and are cheap. Still, they are also associated with drug-drug interactions, according to a new American Heart Association (AHA) scientific statement.

Patients with heart failure may not have to limit their caffeine intake, according to a recent small, randomized study.

The American Heart Association (AHA) and the China Social Assistance Foundation announced Oct. 13 that they would open a training center in China focused on bystander response to cardiac arrest.

Shortly after the release of final ruling on the Medicare Access and CHIP Reauthorization Act (MACRA) Oct. 14, American College of Cardiology (ACC) president Richard A. Chazal, MD, commented on the legislation.